In this webinar hosted by the Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Pasi Jänne, MD, PhD, Julia Rotow, MD, and Mark Awad, MD, PhD, discuss how COVID-19 has impacted patients with thoracic cancer, focusing on the effects it has had on clinical research activities and patient care. Dr. Awad notes that results from the CCC19 study in patients with cancer had a higher risk of death than the general population. Dr. Jänne notes that enrollment into clinical trials has continued with modifications. Dr. Rotow shares considerations for clinical care, including the potential for delays in access to procedures, the need to minimize health care exposures during times of increased infection risk, and the need to reduce the risk of immunosuppression.